Abstract
PTEN is a tumor suppressor gene localized to human chromosome 10q23.31, a genomic region frequently lost in glioblastoma and prostate cancer. The fact that PTEN encodes a lipid phosphatase with specificity towards phosphatidylinositol-3,4,5-triphosphate renders it a gate-keeper of the phosphatidylinositol 3-kinase pathway. Numerous physiological processes have been ascribed to this evolutionarily conserved molecule including proliferation, cell size determination, survival, differentiation, and cell fate specification. Indeed, mutation in PTEN gene is the genetic cause of Cowden Syndrome. Structurally, the 54-kilodalton protein is composed of two major functional domains crucial for catalytic and membrane binding functions. Additional regulatory regions in both amino- and carboxyl-termini further dictate its structural integrity, catalytic activity, and subcellular localization. Extensive characterization of PTEN primary coding sequence has revealed a multitude of post-translational modifications that fine-tune its biochemical properties. These include phosphorylation, ubiquitination, redox modifications, and acetylation. This article aims to provide an indepth review of the diverse post-translational modifications of PTEN, focusing on their biological relevance in both normal and cancer cells. The potential applications to cancer therapy by modulating the post-translational modifications of PTEN will also be discussed.
Keywords: PTEN, phosphatase, tumor suppressor, post-translational, phosphorylation, ubiquitination, redox, acetylation, Acute Myeloid Leukemia, Epidermal Growth Factor Receptor, Glutathione-S-Transferase, Histone acetyltransferase, Promyelocytic Leukemia Protein, Reactive Oxygen Species, Histone deacetylase
Current Cancer Drug Targets
Title: Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Volume: 11 Issue: 5
Author(s): G. Singh and A. M. Chan
Affiliation:
Keywords: PTEN, phosphatase, tumor suppressor, post-translational, phosphorylation, ubiquitination, redox, acetylation, Acute Myeloid Leukemia, Epidermal Growth Factor Receptor, Glutathione-S-Transferase, Histone acetyltransferase, Promyelocytic Leukemia Protein, Reactive Oxygen Species, Histone deacetylase
Abstract: PTEN is a tumor suppressor gene localized to human chromosome 10q23.31, a genomic region frequently lost in glioblastoma and prostate cancer. The fact that PTEN encodes a lipid phosphatase with specificity towards phosphatidylinositol-3,4,5-triphosphate renders it a gate-keeper of the phosphatidylinositol 3-kinase pathway. Numerous physiological processes have been ascribed to this evolutionarily conserved molecule including proliferation, cell size determination, survival, differentiation, and cell fate specification. Indeed, mutation in PTEN gene is the genetic cause of Cowden Syndrome. Structurally, the 54-kilodalton protein is composed of two major functional domains crucial for catalytic and membrane binding functions. Additional regulatory regions in both amino- and carboxyl-termini further dictate its structural integrity, catalytic activity, and subcellular localization. Extensive characterization of PTEN primary coding sequence has revealed a multitude of post-translational modifications that fine-tune its biochemical properties. These include phosphorylation, ubiquitination, redox modifications, and acetylation. This article aims to provide an indepth review of the diverse post-translational modifications of PTEN, focusing on their biological relevance in both normal and cancer cells. The potential applications to cancer therapy by modulating the post-translational modifications of PTEN will also be discussed.
Export Options
About this article
Cite this article as:
Singh G. and M. Chan A., Post-Translational Modifications of PTEN and their Potential Therapeutic Implications, Current Cancer Drug Targets 2011; 11 (5) . https://dx.doi.org/10.2174/156800911795655930
DOI https://dx.doi.org/10.2174/156800911795655930 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Significant Changes in D2-like Dopamine Gene Receptors Expression Associated with Non- Small -Cell Lung Cancer: Could it be of Potential Use in the Design of Future Therapeutic Strategies?
Current Cancer Therapy Reviews Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
Current Pharmaceutical Design Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Fulvestrant - A Novel Endocrine Therapy for Breast Cancer
Current Medicinal Chemistry Protein Cysteine Modifications: (2) Reactivity Specificity and Topics of Medicinal Chemistry and Protein Engineering
Current Medicinal Chemistry Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells
Current Molecular Medicine Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Design, Synthesis and Anticancer Activity Evaluation of Diazepinomicin Derivatives
Letters in Drug Design & Discovery Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals Antiproliferative Activities on Renal, Prostate and Melanoma Cancer Cell Lines of Sarcopoterium spinosum Aerial Parts and its Major Constituent Tormentic Acid
Anti-Cancer Agents in Medicinal Chemistry CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Involvement of MicroRNA Mir15a in Control of Human Ovarian Granulosa Cell Proliferation, Apoptosis, Steroidogenesis, and Response to FSH
MicroRNA